Coloplast A/S (OTCMKTS:CLPBY) Reaches New 52-Week Low – Should You Sell?

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report)’s share price reached a new 52-week low on Thursday . The stock traded as low as $6.10 and last traded at $6.20, with a volume of 28664 shares changing hands. The stock had previously closed at $6.38.

Wall Street Analysts Forecast Growth

CLPBY has been the subject of several research analyst reports. Kepler Capital Markets upgraded Coloplast A/S to a “strong-buy” rating in a research report on Wednesday, May 20th. Sanford C. Bernstein upgraded Coloplast A/S to a “hold” rating in a research report on Wednesday, January 28th. Finally, The Goldman Sachs Group lowered Coloplast A/S from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

Get Coloplast A/S alerts:

Check Out Our Latest Stock Report on CLPBY

Coloplast A/S Trading Down 2.2%

The company’s 50 day simple moving average is $6.56 and its 200 day simple moving average is $7.75. The firm has a market cap of $14.06 billion, a price-to-earnings ratio of 44.57, a P/E/G ratio of 1.99 and a beta of 0.15. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.30 and a quick ratio of 0.81.

Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.09 by $0.01. Coloplast A/S had a net margin of 7.46% and a return on equity of 31.96%. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.11 billion. As a group, research analysts expect that Coloplast A/S Sponsored ADR will post 0.4 earnings per share for the current fiscal year.

About Coloplast A/S

(Get Free Report)

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.

Featured Articles

• Five stocks we like better than Coloplast A/S
• Microsoft Is Spending Billions on AI, But Investors Aren’t Buying It
• Is Co-Diagnostics National Security’s Next Diagnostic Pick?
• If the Market Rally Stalls, This ETF Can Insulate Portfolios
• Semtech’s Explosive Rally May Only Be Getting Started

Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.